189 related articles for article (PubMed ID: 16509531)
1. Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood.
Chan B; Zacharin M
J Pediatr Endocrinol Metab; 2006 Jan; 19(1):75-80. PubMed ID: 16509531
[TBL] [Abstract][Full Text] [Related]
2. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
Pfeilschifter J; Ziegler R
Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942
[TBL] [Abstract][Full Text] [Related]
3. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome.
Lala R; Matarazzo P; Andreo M; Marzari D; Bellone J; Corrias A; de Sanctis C;
J Pediatr Endocrinol Metab; 2006 May; 19 Suppl 2():583-93. PubMed ID: 16789621
[TBL] [Abstract][Full Text] [Related]
5. Pamidronate for fibrous dysplasia due to McCune Albright Syndrome.
Kochar IP; Kulkarni KP
Indian Pediatr; 2010 Jul; 47(7):633-5. PubMed ID: 20683120
[No Abstract] [Full Text] [Related]
6. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
Plotkin H; Rauch F; Zeitlin L; Munns C; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2003 Oct; 88(10):4569-75. PubMed ID: 14557424
[TBL] [Abstract][Full Text] [Related]
7. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
Lala R; Matarazzo P; Bertelloni S; Buzi F; Rigon F; de Sanctis C
Acta Paediatr; 2000 Feb; 89(2):188-93. PubMed ID: 10709889
[TBL] [Abstract][Full Text] [Related]
8. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome.
Zacharin M; O'Sullivan M
J Pediatr; 2000 Sep; 137(3):403-9. PubMed ID: 10969268
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate therapy for fibrous dysplasia.
DiMeglio LA
Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():440-5. PubMed ID: 17982393
[TBL] [Abstract][Full Text] [Related]
10. Recurrent femur neck fracture and response to bisphosphonates in polyostotic fibrous dysplasia.
Rastogi A; Bhadada SK; Bhansali A
Indian J Pediatr; 2012 May; 79(5):667-9. PubMed ID: 21761121
[TBL] [Abstract][Full Text] [Related]
11. Craniofacial fibrous dysplasia: A 10-case series.
Couturier A; Aumaître O; Gilain L; Jean B; Mom T; André M
Eur Ann Otorhinolaryngol Head Neck Dis; 2017 Sep; 134(4):229-235. PubMed ID: 28302454
[TBL] [Abstract][Full Text] [Related]
12. Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia.
Isaia GC; Lala R; Defilippi C; Matarazzo P; Andreo M; Roggia C; Priolo G; de Sanctis C
Calcif Tissue Int; 2002 Aug; 71(2):121-8. PubMed ID: 12200645
[TBL] [Abstract][Full Text] [Related]
13. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X
Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.
Corsi A; Ippolito E; Robey PG; Riminucci M; Boyde A
Skeletal Radiol; 2017 Oct; 46(10):1435-1439. PubMed ID: 28660402
[TBL] [Abstract][Full Text] [Related]
15. Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.
van der Bruggen W; Vriens D; Meier ME; Smit F; Winter EM; de Geus-Oei LF; Appelman-Dijkstra NM
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2980-e2994. PubMed ID: 33788944
[TBL] [Abstract][Full Text] [Related]
16. Lesion Expansion in Gnathic Fibrous Dysplasia: Natural History, Indicators of Progression, and Response to Bisphosphonates.
Pan KS; Taylor J; Szymczuk V; Boyce AM
J Bone Miner Res; 2023 Oct; 38(10):1465-1471. PubMed ID: 37477421
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
[TBL] [Abstract][Full Text] [Related]
18. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases.
Chan B; Zacharin M
J Clin Endocrinol Metab; 2006 Jun; 91(6):2017-20. PubMed ID: 16551739
[TBL] [Abstract][Full Text] [Related]
19. Estimation of bone strength parameters and response to treatment in McCune-Albright syndrome using peripheral quantitative computed tomography of the tibia.
Atsali E; Zoubos AB; Stathopoulos KD; Stefos E; Bournazos I; Papadimitriou A; Nicolaidou P; Skarantavos G
J Clin Densitom; 2012; 15(4):461-466. PubMed ID: 22819140
[No Abstract] [Full Text] [Related]
20. Bisphosphonate treatment in polyostotic fibrous dysplasia of the cranium: case report and literature review.
Mansoori LS; Catel CP; Rothman MS
Endocr Pract; 2010; 16(5):851-4. PubMed ID: 20570808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
